Champions Oncology, Inc. — Form 10-Q Summary
Business context and period. Champions Oncology provides oncology research and development services using its TumorGraft platform and patient-derived xenograft models, primarily for pharmaceutical and biotechnology customers. This report covers the fiscal quarter and six months ended October 31, 2020; comparisons are with the corresponding 2019 periods. Amounts below are in millions of dollars unless stated otherwise.
Financial performance
| Metric | Three months ended Oct. 31, 2020 | Three months ended Oct. 31, 2019 | Six months ended Oct. 31, 2020 | Six months ended Oct. 31, 2019 |
|---|---|---|---|---|
| Revenue | $10.117 | $7.625 | $19.664 | $14.362 |
| Gross margin | 44.2% | 49.1% | 44.2% | 46.9% |
| Operating income (loss) | $0.007 | $0.291 | $0.031 | ($0.323) |
| Net income (loss) | $0.001 | $0.307 | $0.076 | ($0.334) |
| Operating cash flow | Not presented separately | Not presented separately | $0.164 | $0.081 |
- Revenue mix and growth: Pharmacology services generated $10.041 million of quarterly revenue and $19.454 million for the half year. Revenue rose 32.7% for the quarter and 36.9% for the half year, attributed to more and larger studies, expanded platform and product offerings, and more complex study designs. Personalized oncology services revenue declined to $37,000 for the quarter and $150,000 for the half year.
- Costs and margins: Cost of oncology services grew faster than revenue—45.4% for the quarter and 43.8% for the half year—reducing gross margins. Management cited compensation, lab supplies, outsourced lab services, and costs incurred ahead of revenue recognition. R&D and sales and marketing also increased as the company invested in new capabilities, TumorBank characterization, and business development.
- Cash flow and investment: Six-month investing cash outflow was $1.132 million, mainly for laboratory equipment and software. Financing provided $1.179 million, primarily from stock option exercises. Cash increased $0.211 million to $8.553 million.
- Balance sheet and liquidity: At October 31, cash was $8.553 million, working capital was approximately $2.2 million, and accumulated deficit was $72.6 million. Total liabilities were $18.867 million, including $6.537 million of operating lease liabilities; the company reported no off-balance-sheet debt or similar obligations. Management said cash on hand and expected positive fiscal 2021 operating cash flow should fund operations for at least 12 months from the filing, while noting that additional capital might be needed if revenue expectations are not met.
Material changes and notable items
- Revenue growth did not translate into higher quarterly earnings: operating income declined to $7,000 from $291,000, and net income declined to $1,000 from $307,000. For the six-month period, results improved from an operating and net loss to modest income.
- Accounts receivable, net, increased to $5.960 million from $4.770 million at April 30, 2020; deferred revenue increased to $6.188 million from $5.815 million. The six-month operating cash flow included a $1.237 million cash use from accounts receivable.
- The company expanded its Rockville laboratory premises, recognizing approximately $3.8 million of new operating lease assets and liabilities, and terminated a former facility lease, recording a gain of approximately $75,000. Operating lease liabilities totaled $6.537 million at period-end.
- Option exercises generated $1.294 million in proceeds and increased shares outstanding during the half year. The filing reports 13,368,545 shares outstanding at October 31, 2020 and 13,369,045 at December 4, 2020.
Outlook, risks, and other disclosures
- No specific revenue or earnings guidance was provided. Management plans to continue expanding the TumorGraft platform and its TOS program; the POS program is not expected to be a focus of growth.
- Management reported no material adverse business impact from COVID-19 as of the filing, but warned that restrictions, supplier disruptions, delays in biologic materials, and reduced customer or partner activity could affect operations.
- Management said cost reductions could be implemented if revenue expectations are not achieved. If additional capital is required, there is no assurance it can be raised on acceptable terms.
- The company reported no current legal proceedings known to it, no defaults upon senior securities, and effective disclosure controls as of October 31, 2020. It maintained a full valuation allowance against deferred tax assets and disclosed $180,000 of uncertain tax-position liabilities.
Important facts for investors to verify
- Whether study growth and larger, more complex contracts can sustain revenue growth and improve gross margins, given service costs have grown faster than revenue.
- How accounts receivable and unbilled services convert to cash, and whether operating cash flow remains positive as investment spending continues.
- Whether management’s expectation of positive fiscal 2021 operating cash flow and at least 12 months of liquidity remains achievable if revenue, customer activity, or collections weaken.
- The ongoing cost and utilization of the expanded laboratory space and the company’s resulting lease commitments.
- Potential COVID-19 effects on customers, suppliers, biologic-material shipments, and laboratory operations.